Elan (ELN) implied volatility Elevated into Phase 3 for Alzheimer's

Article Stock Quotes (2) Comments (0)

Elan (NYSE: ELN) : ELN, a neuroscience-based biotechnology company, is recently at $18.40 in pre-open trading, above its close of $16.60. SBSH say's "ELN & WYE announced overnight that the companies have decided to move bapineuzumab, their most advanced program for the treatment of Alzheimer's disease, into Phase 3 clinical development." ELN June option implied volatility of 57 is near its 26-week average, above its 3-month average of 52 according to Track Data. Paul Foster

You May Also Be Interested In

• Elan (ELN) Rejects Royalty Pharma's $12.50/Share Bid
• A Tradable Relief Rally in the Gold Miners (GDX)?
• Echo Pharma Lowers Acceptance Threshold in Elan (ELN) Bid to 50%

Create E-mail Alert Related Categories

Options

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?